Frontiers in Cardiovascular Medicine (Dec 2022)

Clinical efficacy of sacubitril-valsartan combined with acute ST-segment elevation myocardial infarction after reperfusion: A systematic review and meta-analysis

  • Dong Zhang,
  • Dong Zhang,
  • Hui Wu,
  • Hui Wu,
  • Di Liu,
  • Di Liu,
  • Yunzhao Li,
  • Yunzhao Li,
  • Gang Zhou,
  • Gang Zhou,
  • QingZhuo Yang,
  • QingZhuo Yang,
  • YanFang Liu,
  • YanFang Liu

DOI
https://doi.org/10.3389/fcvm.2022.1036151
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundSeveral studies have investigated the combined use of sacubitril- valsartan after reperfusion in acute ST-segment elevation myocardial infarction (STEMI). However, the sample sizes of these studies were small and their results were somewhat heterogeneous. To determine the effect of sacubitril-valsartan on myocardial ischemia-reperfusion.MethodsSearch PubMed, EMbase, Web of Science and The Cochrane Library, CNKI database, VIP database and Wanfang digital journal full-text database for eligible articles from their date of inception up to April, 2022. All data were meta-analyzed using Review Manager 5.3 and STATA 16.0 software.ResultsA total of 23 studies including 2,326 patients with acute STEMI were included. These results of this meta-analysis indicated that left ventricular ejection fractions (LVEF) value within 6 months after surgery (OR, 4.29; 95% confidence interval, 3.78–4.80; P < 0.00001), left ventricular end-diastolic diameter (LVEDD) value within 6 months after surgery (OR, −3.11; 95% CI, −3.87 to −2.35; P < 0.00001) and left ventricular end-diastolic volume (LVEDV) value 6 months after operation (OR, −6.22; 95% CI, −7.10 to −5.35; P < 0.00001) are better than without sacubitril and valsartan.ConclusionTo sum up the above, the results of this study suggest that sacubitril- valsartan can reduce the reperfusion injury of ischemic myocardium by improving cardiac function within a follow-up period of 6 months.

Keywords